Halberd Corp. (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements (OTCID)
Halberd holds the exclusive rights to 4 granted U.S. Patents: no. 9,216,386 / no. 8,758,287 / no. 11,186,629 / no. 8,865,733 and 22 pending provisional patents
Halberd Corporation is a biotechnology research company and with its partners (Dr. Qiang Shawn Chen and his team at Arizona State University; Dr. William Sturrus and his team at Youngstown State University; Dr. Richard Carr and his team at Mississippi State University), is developing multiple treatments against PTSD, CTE, Alzheimer's Disease and other virusses and diseases:
Athena Telemedicine Partners LLC:
2024/2025: In close cooperation with partner (revenue sharing agreement in place) AthenaGTX, Halberd Corp is working on contracts from the military, to develop treatments to tackle Post Traumatic Stress Syndrome/PTSD and other diseases following head trauma. Key words are LDX and WatchDawg.
Mississippi State University:
2024/2025: Research Partner MSU is leading pre-clinical (animal) trials for Halberd's patent-pending nasal spray, called Tri-Ax. The three-component nasal spray mitigates the potential neurodegenerative cascade following head trauma. Animal tests at MSU with Halberd's nasal spray have achieved over 50% reduction in GlialFiblliary Acid Protein GFAP), the gold standard indicator of brain injury following head trauma. This product addresses an unmet need for use in the military, by first responders and contact sports teams.
Halberd Corp. and AthenaGTX filed several funding proposals for both treatments with multiple defense departments (ONR/US Army), but is also working on securing private funding
Market Data 
Markets 
AI
